Logo - springer
Slogan - springer

| Drugs in R&D (Editorial Board)

Drugs in R&D

Drugs in R&D

Editor: Anton van Rensburg

ISSN: 1174-5886 (print version)
ISSN: 1179-6901 (electronic version)

Journal no. 40268

G. An, University of Iowa, Iowa, IA, USA

R.K. Campbell, Washington State University, Pullman, WA, USA

D. Cattaneo, Luigi Sacco University Hospital, Milan, Italy

G. Cherala, Eastern Virginia Medical School, Norfolk, VA, USA

R.P. Dash, Johns Hopkins School of Medicine, Baltimore, MD, USA

Y.K. Gupta, All India Institute of Medical Sciences, New Delhi, India

H.P. Hartung, Heinrich-Heine University, Dusseldorf, Germany

C. Höcht, University of Buenos Aires, Buenos Aires, Agentina

N.M. Idkaidek, University of Petra, Amman, Jordan

F. Jamali, University of Alberta, Edmonton, AB, Canada

T.K.L. Kiang, The University of British Columbia, Vancouver, BC, Canada

M.J. McKeage, University of Auckland, Auckland, New Zealand

P.J. Nathan, Monash University, Melbourne, VIC, Australia

B.M. Patel, Nirma University, Ahmedabad, India

S. Perez-Lloret, Institute for Cardiology Research, National Research Council (ININCA-UBA-CONICET), Buenos Aires, Argentina

M. Pfister, University of Basel, Basel, Switzerland

G. Remington, University of Toronto, Toronto, ON, Canada

H. Schütz, BEBAC Consulting, Vienna, Austria

M.H. Shishehbor, Cleveland Clinic Cardiovascular Disease, Cleveland, OH, USA

L.P. Shulman, Feinberg School of Medicine of Northwestern University, Chicago, IL, USA

L. Tóthfalusi, Semmelweis University, Budapest, Hungary

R. Vats, Hyderabad Campus, Hyderabad, India

J. Weiss, University of Heidelberg, Heidelberg, Germany

For authors and editors

  • Aims and Scope

    Aims and Scope


    Drugs in R&D is an international, peer reviewed, open access, online only journal, and provides timely information from all phases of drug research and development that will inform clinical practice. Healthcare decision makers are thus provided with knowledge about the developing place of a drug in therapy.

    The Journal includes:

    • Clinical research on new and established drugs;
    • Preclinical research of direct relevance to clinical drug development;
    • Short communications and case study reports that meet the above criteria will also be considered;
    • Reviews may also be considered.

    Articles published in Drugs in R&D may be accompanied by plain language summaries, to assist patients, caregivers and others in understanding important medical advances. 

    The journal will consider fee discounts for developing countries and this is decided on a case by case basis.

    All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.

  • Submit Online
  • Instructions for Authors

    Instructions for Authors


  • Important Information for Authors

    Important Information for Authors


  • Disclosure of potential conflicts of int...
  • Copyright Information

    Copyright Information


    Copyright and Licence Agreement

    Open Access Drugs in R&D is published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, go to: http://creativecommons. org/licenses/by-nc/4.0

    Journal ownership: Springer International Publishing Switzerland

    Copyright of articles: © The Author(s)

Additional information